EP3027193A4 - Therapeutically active compounds and their methods of use - Google Patents

Therapeutically active compounds and their methods of use Download PDF

Info

Publication number: EP3027193A4
Authority: EP; European Patent Office
Prior art keywords: methods; active compounds; therapeutically active; therapeutically; compounds
Prior art date: 2013-08-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP14832505.3A

Other languages

German (de)

French (fr)

Other versions

EP3027193A2 (en

Inventor

Samuel V. AGRESTA

Chong-Hui Gu

David SCHENKEIN

Hua Yang

Liting GUO

Zhen Tang

Jianming Wang

Yanfeng Zhang

Yan Zhou

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Agios Pharmaceuticals Inc

Original Assignee

Agios Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-08-02

Filing date

2014-08-01

Publication date

2017-04-26

2013-08-09 Priority claimed from PCT/CN2013/081170 external-priority patent/WO2015018060A1/en

2014-08-01 Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc

2014-08-01 Priority to EP21178745.2A priority Critical patent/EP3932408A1/en

2014-08-01 Priority to EP19177845.5A priority patent/EP3566706B1/en

2016-06-08 Publication of EP3027193A2 publication Critical patent/EP3027193A2/en

2017-04-26 Publication of EP3027193A4 publication Critical patent/EP3027193A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Oncology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

EP14832505.3A 2013-08-02 2014-08-01 Therapeutically active compounds and their methods of use Withdrawn EP3027193A4 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
EP21178745.2A EP3932408A1 (en)	2013-08-02	2014-08-01	Therapeutically active compounds and their methods of use
EP19177845.5A EP3566706B1 (en)	2013-08-02	2014-08-01	Therapeutically active compounds and their methods of use

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201361861884P	2013-08-02	2013-08-02
PCT/CN2013/081170 WO2015018060A1 (en)	2013-08-09	2013-08-09	Crystalline forms of therapeutically active compounds and use thereof
US201461939098P	2014-02-12	2014-02-12
US201461975448P	2014-04-04	2014-04-04
US201462011948P	2014-06-13	2014-06-13
PCT/US2014/049469 WO2015017821A2 (en)	2013-08-02	2014-08-01	Therapeutically active compounds and their methods of use

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
EP21178745.2A Division EP3932408A1 (en)	2013-08-02	2014-08-01	Therapeutically active compounds and their methods of use
EP19177845.5A Division EP3566706B1 (en)	2013-08-02	2014-08-01	Therapeutically active compounds and their methods of use

Publications (2)

Publication Number	Publication Date
EP3027193A2 EP3027193A2 (en)	2016-06-08
EP3027193A4 true EP3027193A4 (en)	2017-04-26

Family

ID=52432592

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP19177845.5A Active EP3566706B1 (en)	2013-08-02	2014-08-01	Therapeutically active compounds and their methods of use
EP14832505.3A Withdrawn EP3027193A4 (en)	2013-08-02	2014-08-01	Therapeutically active compounds and their methods of use
EP21178745.2A Pending EP3932408A1 (en)	2013-08-02	2014-08-01	Therapeutically active compounds and their methods of use

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP19177845.5A Active EP3566706B1 (en)	2013-08-02	2014-08-01	Therapeutically active compounds and their methods of use

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP21178745.2A Pending EP3932408A1 (en)	2013-08-02	2014-08-01	Therapeutically active compounds and their methods of use

Country Status (21)

Country	Link
US (5)	US9738625B2 (en)
EP (3)	EP3566706B1 (en)
JP (3)	JP6742905B2 (en)
CN (3)	CN110372670B (en)
AU (2)	AU2014295938B2 (en)
BR (1)	BR112016002287A2 (en)
CA (1)	CA2919382A1 (en)
CL (2)	CL2016000263A1 (en)
EA (1)	EA030428B1 (en)
ES (1)	ES2886211T3 (en)
IL (2)	IL243833A0 (en)
MX (2)	MX394658B (en)
MY (1)	MY177994A (en)
NI (1)	NI201600022A (en)
PE (1)	PE20160840A1 (en)
PH (1)	PH12016500164B1 (en)
SA (1)	SA516370523B1 (en)
SG (2)	SG11201600479WA (en)
TW (2)	TWI666208B (en)
UA (1)	UA121021C2 (en)
WO (1)	WO2015017821A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015003360A2 (en)	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
ES2886211T3 (en) *	2013-08-02	2021-12-16	Agios Pharmaceuticals Inc	Therapeutically active compounds and their methods of use
JP2017529382A (en)	2014-09-29	2017-10-05	アギオスファーマシューティカルス，インコーポレーテッド	Compounds having therapeutic activity and methods of use thereof
KR102628370B1 (en)	2015-02-04	2024-01-24	르 라보레또레 쎄르비에르	Therapeutically active compounds and methods of their use
US20180134683A1 (en) *	2015-05-07	2018-05-17	Teligene Ltd.	Heterocylcic compounds as idh2 inhibitors
HUE056537T2 (en) *	2015-07-30	2022-02-28	Chia Tai Tianqing Pharmaceutical Group Co Ltd	1, 3, 5-triazine derivative and method of using same
US9751863B2 (en)	2015-08-05	2017-09-05	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
CA3002029A1 (en) *	2015-10-15	2017-04-20	Celgene Corporation	Combination therapy for treating malignancies
IL311873A (en) *	2015-10-15	2024-06-01	Agios Pharmaceuticals Inc	Combined therapy for the treatment of malignancies
CA3002531C (en) *	2015-10-21	2020-08-18	NeuForm Pharmaceuticals, Inc.	Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof
IL299563A (en)	2015-12-04	2023-02-01	Agios Pharmaceuticals Inc	Methods for the treatment of acute myeloid leukemia characterized by the presence of a mutant allele of IDH2 and the absence of a mutant allele of NRAS
WO2017140758A1 (en)	2016-02-19	2017-08-24	Debiopharm International S.A.	Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
CA3015753A1 (en) *	2016-02-26	2017-08-31	Celgene Corporation	Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
US20180042930A1 (en)	2016-08-03	2018-02-15	Celgene Corporation	Methods of treatment of malignancies
JP7093764B2 (en) *	2016-08-03	2022-06-30	セルジーンコーポレイション	How to treat myelodysplastic syndrome
BR112019004356A2 (en) *	2016-09-07	2019-05-28	Celgene Corporation	tablet compositions
EP3572409B1 (en) *	2017-01-22	2022-07-20	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	1,3,5-triazine derivative salt, crystal, preparation method, pharmaceutical composition and use thereof
EP3618828B1 (en)	2017-05-05	2023-11-01	Memorial Sloan Kettering Cancer Center	Methods of treatment of myeloproliferative neoplasm
CA3068591A1 (en)	2017-06-30	2019-01-03	Celgene Corporation	Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
CN109467538A (en)	2017-09-07	2019-03-15	和记黄埔医药（上海）有限公司	Cycloalkene-substituted heteroaromatic compounds and their uses
US20220017490A1 (en)	2018-11-02	2022-01-20	Celgene Corporation	Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US12215094B2 (en)	2018-11-02	2025-02-04	Celgene Corporation	Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220017489A1 (en)	2018-11-02	2022-01-20	Celgene Corporation	Solid dispersions for treatment of cancer
EP4058028B1 (en)	2019-11-14	2025-03-05	Celgene Corporation	Pediatric formulations for treatment of cancer
CN114773320A (en) *	2022-05-29	2022-07-22	重庆医科大学	1,3,5-triazine compound, preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130190287A1 (en) *	2012-01-06	2013-07-25	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2390529A (en)	1942-02-03	1945-12-11	Ernst A H Friedheim	Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS58186682A (en)	1982-04-27	1983-10-31	日本化薬株式会社	Dyeing of cellulose or cellulose containing fiber material
DE3512630A1 (en)	1985-04-06	1986-10-23	Hoechst Ag, 6230 Frankfurt	METHOD FOR COLORING OR PRINTING CELLULOSE FIBERS OR CELLULOSE MIXED FIBERS
DE59106971D1 (en)	1990-07-12	1996-01-11	Ciba Geigy Ag	Process for the photochemical and thermal stabilization of polyamide fiber materials.
JPH11158073A (en)	1997-09-26	1999-06-15	Takeda Chem Ind Ltd	Adenosine a3 antagonist
EP1187825A1 (en)	1999-06-07	2002-03-20	Shire Biochem Inc.	Thiophene integrin inhibitors
US7291616B2 (en) *	2001-10-31	2007-11-06	Cell Therapeutics, Inc.	Aryl triazines as LPAAT-β inhibitors and uses thereof
DK2256108T3 (en)	2002-07-18	2016-04-11	Janssen Pharmaceutica Nv	Substituted triazinkinaseinhibitorer
BRPI0810921A2 (en)	2007-04-30	2014-10-29	Prometic Biosciences Inc	Triazine derivatives, compositions containing such derivatives and methods of treating cancer and autoimmune diseases using such compounds
GB0805477D0 (en)	2008-03-26	2008-04-30	Univ Nottingham	Pyrimidines triazines and their use as pharmaceutical agents
CA2764785C (en)	2009-06-08	2015-10-27	California Capital Equity, Llc	Triazine derivatives and their therapeutical applications
EP2451802A1 (en) *	2009-07-07	2012-05-16	Pathway Therapeutics, Inc.	Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2013133367A1 (en)	2012-03-09	2013-09-12	カルナバイオサイエンス株式会社	Novel triazine derivative
KR102302091B1 (en)	2013-07-11	2021-09-16	아지오스 파마슈티컬스 아이엔씨.	N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en)	2013-07-11	2017-02-28	Agios Pharmaceuticals, Inc	Therapeutically active compounds and their methods of use
ES2886211T3 (en)	2013-08-02	2021-12-16	Agios Pharmaceuticals Inc	Therapeutically active compounds and their methods of use
JP2017529382A (en) *	2014-09-29	2017-10-05	アギオスファーマシューティカルス，インコーポレーテッド	Compounds having therapeutic activity and methods of use thereof
KR102628370B1 (en)	2015-02-04	2024-01-24	르 라보레또레 쎄르비에르	Therapeutically active compounds and methods of their use

2014
- 2014-08-01 ES ES19177845T patent/ES2886211T3/en active Active
- 2014-08-01 TW TW103126335A patent/TWI666208B/en active
- 2014-08-01 AU AU2014295938A patent/AU2014295938B2/en active Active
- 2014-08-01 EA EA201690322A patent/EA030428B1/en not_active IP Right Cessation
- 2014-08-01 CN CN201910707312.9A patent/CN110372670B/en active Active
- 2014-08-01 UA UAA201601999A patent/UA121021C2/en unknown
- 2014-08-01 WO PCT/US2014/049469 patent/WO2015017821A2/en not_active Ceased
- 2014-08-01 US US14/909,451 patent/US9738625B2/en active Active
- 2014-08-01 TW TW108110624A patent/TWI701242B/en active
- 2014-08-01 MX MX2020011397A patent/MX394658B/en unknown
- 2014-08-01 EP EP19177845.5A patent/EP3566706B1/en active Active
- 2014-08-01 SG SG11201600479WA patent/SG11201600479WA/en unknown
- 2014-08-01 CN CN201480053796.5A patent/CN105916507A/en active Pending
- 2014-08-01 CN CN201910708167.6A patent/CN110386922A/en active Pending
- 2014-08-01 MY MYPI2016700311A patent/MY177994A/en unknown
- 2014-08-01 CA CA2919382A patent/CA2919382A1/en not_active Abandoned
- 2014-08-01 PE PE2016000214A patent/PE20160840A1/en not_active Application Discontinuation
- 2014-08-01 PH PH1/2016/500164A patent/PH12016500164B1/en unknown
- 2014-08-01 SG SG10201709187TA patent/SG10201709187TA/en unknown
- 2014-08-01 MX MX2016001361A patent/MX389250B/en unknown
- 2014-08-01 EP EP14832505.3A patent/EP3027193A4/en not_active Withdrawn
- 2014-08-01 EP EP21178745.2A patent/EP3932408A1/en active Pending
- 2014-08-01 JP JP2016531940A patent/JP6742905B2/en active Active
- 2014-08-01 BR BR112016002287A patent/BR112016002287A2/en not_active Application Discontinuation
2016
- 2016-01-28 IL IL243833A patent/IL243833A0/en unknown
- 2016-02-01 NI NI201600022A patent/NI201600022A/en unknown
- 2016-02-01 SA SA516370523A patent/SA516370523B1/en unknown
- 2016-02-02 CL CL2016000263A patent/CL2016000263A1/en unknown
2017
- 2017-07-13 US US15/649,551 patent/US10093654B2/en active Active
- 2017-09-04 CL CL2017002240A patent/CL2017002240A1/en unknown
2018
- 2018-09-04 US US16/121,483 patent/US10730854B2/en active Active
- 2018-10-10 AU AU2018247242A patent/AU2018247242B2/en active Active
2019
- 2019-04-24 JP JP2019082794A patent/JP2019142930A/en not_active Withdrawn
- 2019-10-31 IL IL270347A patent/IL270347B/en unknown
2020
- 2020-06-29 US US16/915,936 patent/US20210155603A1/en not_active Abandoned
2021
- 2021-07-29 JP JP2021123814A patent/JP2021176893A/en active Pending
2023
- 2023-05-08 US US18/144,695 patent/US20240132474A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130190287A1 (en) *	2012-01-06	2013-07-25	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number	Publication date
EP3566706B1 (en)	2021-07-14
BR112016002287A2 (en)	2017-08-01
PE20160840A1 (en)	2016-09-22
CA2919382A1 (en)	2015-02-05
JP2016527279A (en)	2016-09-08
JP2019142930A (en)	2019-08-29
CN110372670A (en)	2019-10-25
PH12016500164A1 (en)	2016-04-25
JP2021176893A (en)	2021-11-11
EA030428B1 (en)	2018-08-31
MX2016001361A (en)	2016-06-14
US20170305885A1 (en)	2017-10-26
US10730854B2 (en)	2020-08-04
EP3932408A1 (en)	2022-01-05
EA201690322A1 (en)	2016-07-29
US9738625B2 (en)	2017-08-22
PH12016500164B1 (en)	2023-11-08
UA121021C2 (en)	2020-03-25
EP3027193A2 (en)	2016-06-08
AU2018247242B2 (en)	2020-03-12
IL243833A0 (en)	2016-04-21
IL270347B (en)	2021-08-31
MX394658B (en)	2025-03-24
AU2014295938B2 (en)	2018-07-19
MY177994A (en)	2020-09-28
WO2015017821A2 (en)	2015-02-05
TWI701242B (en)	2020-08-11
TW201932455A (en)	2019-08-16
SA516370523B1 (en)	2019-01-10
CN110372670B (en)	2023-04-07
US10093654B2 (en)	2018-10-09
SG10201709187TA (en)	2017-12-28
AU2014295938A1 (en)	2016-02-18
US20210155603A1 (en)	2021-05-27
US20240132474A1 (en)	2024-04-25
MX2020011397A (en)	2022-08-05
US20160194305A1 (en)	2016-07-07
WO2015017821A3 (en)	2015-04-09
AU2018247242A1 (en)	2018-11-01
TWI666208B (en)	2019-07-21
MX389250B (en)	2025-03-20
SG11201600479WA (en)	2016-02-26
CL2016000263A1 (en)	2016-08-19
TW201524971A (en)	2015-07-01
CN110386922A (en)	2019-10-29
NI201600022A (en)	2016-03-16
NZ716226A (en)	2021-08-27
CL2017002240A1 (en)	2018-04-20
CN105916507A (en)	2016-08-31
ES2886211T3 (en)	2021-12-16
EP3566706A1 (en)	2019-11-13
JP6742905B2 (en)	2020-08-19
US20180370951A1 (en)	2018-12-27

Publication	Publication Date	Title
IL270347B (en)	2021-08-31	Therapeutically active compounds and their methods of use
ZA202100373B (en)	2023-04-26	Therapeutically active compounds and their methods of use
EP3019483A4 (en)	2017-01-11	Therapeutically active compounds and their methods of use
EP3406608B8 (en)	2022-01-19	Therapeutically active compounds and their methods of use
EP2804850A4 (en)	2015-09-23	Therapeutically active compounds and their methods of use
EP3074377A4 (en)	2017-04-19	Substituted benzamides and methods of use thereof
EP3065875A4 (en)	2018-02-07	Bioprinter and methods of using same
EP3046921A4 (en)	2017-02-22	Substituted aminopyrimidine compounds and methods of use
IL251246A0 (en)	2017-05-29	Therapeutically active compounds and their methods of use
IL253796A0 (en)	2017-09-28	Therapeutically active compounds and their methods of use
EP3062618A4 (en)	2017-07-12	Crystalline forms of therapeutic compounds and uses thereof
EP3035968A4 (en)	2017-04-19	Telodendrimers and nanocarriers and methods of using same
EP3054974A4 (en)	2017-06-14	Glycan-interacting compounds and methods of use
EP3019477A4 (en)	2017-01-11	Heterocyclic compounds and methods of their use
EP3038622A4 (en)	2017-04-12	Heterocyclic compounds and methods of use
EP3086647A4 (en)	2017-08-02	Antimicrobial substrates and methods of use thereof
EP3027182A4 (en)	2017-04-12	Novel copper-cysteamine and methods of use
EP3065674A4 (en)	2017-11-22	Monolithic medical devices and methods of use
EP3060924A4 (en)	2017-05-24	Pif-transfected cells and methods of use
EP3062795A4 (en)	2017-05-31	Crystalline forms of therapeutic compounds and uses thereof
EP3104869A4 (en)	2017-11-15	Treatment of pain
EP3065873A4 (en)	2017-07-05	Multiple tube devices and methods of manufacture and use
EP3073825A4 (en)	2017-06-21	Inhibitors of ercc1-xpf and methods of using the same
EP2986309A4 (en)	2017-03-08	Peptide compounds and methods of production and use thereof
EP3052475A4 (en)	2017-05-03	Pharmaceutical use of 3-benzylsulfonylpropionitrile

Legal Events

Date	Code	Title	Description
2016-05-06	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-06-08	17P	Request for examination filed	Effective date: 20160229
2016-06-08	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-06-08	AX	Request for extension of the european patent	Extension state: BA ME
2016-11-09	DAX	Request for extension of the european patent (deleted)
2017-04-26	A4	Supplementary search report drawn up and despatched	Effective date: 20170329
2017-04-26	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/5377 20060101AFI20170323BHEP Ipc: C07D 401/14 20060101ALI20170323BHEP Ipc: A61K 31/53 20060101ALI20170323BHEP Ipc: C07D 401/12 20060101ALI20170323BHEP
2017-08-25	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1224582 Country of ref document: HK
2018-01-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-02-14	17Q	First examination report despatched	Effective date: 20180116
2018-04-04	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: AGIOS PHARMACEUTICALS, INC.
2019-10-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2019-11-20	18D	Application deemed to be withdrawn	Effective date: 20190615